What is important is the half-life which is 10 days. At 3 days you see around 70% occupancy peaking at 100% at 7 days. Between 7 and 10 days you still have a substantial amount of leronlimab in your system to bind to new cells that express CCR5. At day 7 with the second dose it ramps up to 70% in 3 days overlapping the previous dose to provide 100% coverage. As long as you maintain that overlap you have at or near 100% coverage.

The problem with 2 doses is you'll start seeing a degradation of receptor occupancy after 14 days.